Tags

Type your tag names separated by a space and hit enter

Use of neuraminidase inhibitors to combat pandemic influenza.
J Antimicrob Chemother. 2006 Nov; 58(5):911-5.JA

Abstract

Since the last influenza pandemic in 1968, neuraminidase (NA) inhibitors have been licensed for the treatment and prophylaxis of seasonal influenza. Continuing outbreaks of highly pathogenic avian influenza H5N1 since 2004 have focused attention on the timing of the next pandemic and preparedness plans. Although immunization is the principal means of influenza prophylaxis, a well-matched efficacious vaccine is unlikely to be widely available for several months following the emergence of the pandemic strain. NA inhibitors could be used to contain and eliminate an emerging pandemic virus at source. If unsuccessful, they could still play a crucial role in reducing the medical impact of pandemic influenza as it spreads through countries. Accordingly, many authorities are creating stockpiles of NA inhibitors. However, the use of stockpiled drugs for treatment or prophylaxis, the rapid delivery to newly diagnosed cases and unknown characteristics of an emergent pandemic strain pose significant challenges to determining optimal use of stockpiles.

Authors+Show Affiliations

Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16956904

Citation

Democratis, Jane, et al. "Use of Neuraminidase Inhibitors to Combat Pandemic Influenza." The Journal of Antimicrobial Chemotherapy, vol. 58, no. 5, 2006, pp. 911-5.
Democratis J, Pareek M, Stephenson I. Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother. 2006;58(5):911-5.
Democratis, J., Pareek, M., & Stephenson, I. (2006). Use of neuraminidase inhibitors to combat pandemic influenza. The Journal of Antimicrobial Chemotherapy, 58(5), 911-5.
Democratis J, Pareek M, Stephenson I. Use of Neuraminidase Inhibitors to Combat Pandemic Influenza. J Antimicrob Chemother. 2006;58(5):911-5. PubMed PMID: 16956904.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of neuraminidase inhibitors to combat pandemic influenza. AU - Democratis,Jane, AU - Pareek,Manish, AU - Stephenson,Iain, Y1 - 2006/09/06/ PY - 2006/9/8/pubmed PY - 2007/3/9/medline PY - 2006/9/8/entrez SP - 911 EP - 5 JF - The Journal of antimicrobial chemotherapy JO - J. Antimicrob. Chemother. VL - 58 IS - 5 N2 - Since the last influenza pandemic in 1968, neuraminidase (NA) inhibitors have been licensed for the treatment and prophylaxis of seasonal influenza. Continuing outbreaks of highly pathogenic avian influenza H5N1 since 2004 have focused attention on the timing of the next pandemic and preparedness plans. Although immunization is the principal means of influenza prophylaxis, a well-matched efficacious vaccine is unlikely to be widely available for several months following the emergence of the pandemic strain. NA inhibitors could be used to contain and eliminate an emerging pandemic virus at source. If unsuccessful, they could still play a crucial role in reducing the medical impact of pandemic influenza as it spreads through countries. Accordingly, many authorities are creating stockpiles of NA inhibitors. However, the use of stockpiled drugs for treatment or prophylaxis, the rapid delivery to newly diagnosed cases and unknown characteristics of an emergent pandemic strain pose significant challenges to determining optimal use of stockpiles. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/16956904/Use_of_neuraminidase_inhibitors_to_combat_pandemic_influenza_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkl376 DB - PRIME DP - Unbound Medicine ER -